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ABSTRACT
Type II topoisomerases regulate DNA supercoiling
and chromosome segregation. They act as ATP-
operated clamps that capture a DNA duplex and
pass it through a transient DNA break in a second
DNA segment via the sequential opening and
closure of ATPase-, G-DNA- and C-gates. Here, we
present the first ‘open clamp’ structures of a 3-gate
topoisomerase II-DNA complex, the seminal complex
engaged in DNA recognition and capture. A high-
resolution structure was solved for a (full-length
ParE-ParC55)2 dimer of Streptococcus pneumoniae
topoisomerase IV bound to two DNA molecules: a
closed DNA gate in a B-A-B form double-helical con-
formation and a second B-form duplex associated
with closed C-gate helices at a novel site neighbour-
ing the catalytically important b-pinwheel DNA-
binding domain. The protein N gate is present in an
‘arms-wide-open’ state with the undimerized
N-terminal ParE ATPase domains connected to
TOPRIM domains via a flexible joint and folded
back allowing ready access both for gate and trans-
ported DNA segments and cleavage-stabilizing anti-
bacterial drugs. The structure shows the molecular
conformations of all three gates at 3.7 A˚, the highest
resolution achieved for the full complex to date, and
illuminates the mechanism of DNA capture and
transport by a type II topoisomerase.
INTRODUCTION
Type II DNA topoisomerases catalyse the transport
of one DNA double helix through another in an
ATP-dependent reaction (1–4). This manoeuvre allows
the control of chromosomal DNA supercoiling and the
removal of DNA supercoils, knots and catenanes
generated in a variety of biological processes including
DNA replication, transcription and recombination (1–4).
Type II enzymes are ubiquitous in nature, are biologically
essential and share structural and evolutionary features in
common (5). Topoisomerase (topo) IV and gyrase are the
type II enzymes expressed in bacteria (2,3). Topo IV
mediates the unlinking of daughter chromosomes before
cell division, whereas gyrase is unique in its ability to
introduce negative supercoils into DNA thereby
controlling chromosome supercoiling, which promotes
replication fork advance and allows global regulation of
gene expression. In each case, the active complex is a
tetramer of two topo IV ParC and ParE subunits or
gyrase GyrA and GyrB proteins. The ParC and GyrA
subunits have an N-terminal DNA breakage-reunion
domain linked to divergent C-terminal b-pinwheel
domains that favour intermolecular DNA passage by
topo IV causing DNA unlinking but intramolecular
DNA transport by gyrase producing supercoiled DNA
(6). By contrast, the N-terminal and C-terminal regions
of the highly conserved ParE (GyrB) subunits form the
ATPase- and Mg2+-binding-TOPRIM domains, respect-
ively. These four functional domains are also present in
eukaryotic topo II (2–4,7) but contained within each
subunit of the homodimeric complex organized in a
‘GyrB-GyrA’ arrangement, i.e. N-terminal ATPase-
TOPRIM-breakage/reunion-C-terminal domain. Thus,
different type II topoisomerases share close functional
and architectural similarities.
Early studies of Escherichia coli gyrase and eukaryotic
topo II showed that the salient feature of type II topo-
isomerases is the formation of a transient DNA break
involving a covalent-enzyme DNA intermediate termed
the ‘cleavage complex’(8–10). Stabilization of the
cleavage complex with antibacterial quinolones or
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anticancer topoisomerase inhibitors (11–14) has revealed
that the DNA (known as the G-DNA or G-segment)
contains a 4-bp staggered break formed by covalent
attack and linkage of active site tyrosines, one to each
50 phosphate end. DNA scission allows transport of a
second DNA helix (known as the T-segment or trans-
ported DNA) through the break before resealing of the
gate-DNA (2,3,8–10). It was argued that protein–protein
contacts within the topoisomerase complex must exist to
prevent inadvertent release of lethal DNA breaks and that
the T-segment exits by passage between subunit interfaces
(9,15). Evidence has accumulated that T-segment trans-
port through the topoisomerase complex is coupled to
the concerted opening and closure of two protein
gates—the N-gate formed by the N-terminal ATPase
domains and the C-gate formed within the ParC/GyrA
region. These features have led to a generic mechanism
for type II topoisomerases (Figure 1) (2,3).
It is proposed that the enzyme acts as an ATP-operated
protein clamp that captures DNA for transport. First, the
‘open clamp’ state of the enzyme binds the gate-DNA in a
highly bent conformation through interactions with
the breakage-reunion and TOPRIM domains (1 in
Figure 1). Binding of ATP leads to dimerization of
ATPase domains shutting the N-gate and capturing a
T-segment in the ‘closed enzyme clamp’ (2). DNA
capture allows transport through the opened DNA gate
(3). Resealing of the DNA gate and opening of the C-gate
facilitates release of the T segment (4). Finally, closure of
the C-gate and release of ADP opens the N-gate
converting the closed clamp (4) into the open clamp con-
formation (1) ready for another cycle.
The model describes the reaction mechanism but only in
outline, and many key aspects of the reaction cycle are
uncertain having been inferred by extrapolation from
structures of individual domains trapped and stabilized
using drugs, non-hydrolysable ATP analogues or suicide
DNA substrates (16–19). In particular, the structures of
the various open and closed clamp conformations of the
enzyme and their sequential relationship in catalysis
remain to be established. Available data from electron
microscopy and small angle X-ray scattering are at very
low resolution (20–22). Clearly, high-resolution X-ray
crystal structures of full native topoisomerase II-DNA
reaction intermediates will be essential in understanding
the conformational transitions necessary for catalysis. A
recent structure of yeast topoisomerase II (lacking the
C-terminal domain) bound to a non-hydrolysable ATP
analogue and suicide DNA substrate has provided infor-
mation on a putative late-stage ‘closed’ enzyme clamp (23)
(perhaps equivalent to state 3 in Figure 1). However, high-
resolution structures for other reaction intermediates such
as the open clamp state relevant to early events in catalysis
have remained elusive.
To address this issue, we have focused on topo IV from
Streptococcus pneumoniae, a Gram-positive human
pathogen responsible for life-threatening infections, and
for which topo IV is a target for clinically important
anti-pneumococcal quinolones such as levoﬂoxacin
(24–26). Well-developed biochemistry for recombinant
S. pneumoniae ParC and ParE subunits/domains (27–30)
and strongly cleaved gate-DNA sequences such as the
chromosomal E site (31) and plasmid V site (32) have
made it an appealing system for mechanistic and X-ray
crystallographic studies. Indeed, the ﬁrst crystal structures
for cleavage complexes of a type II topoisomerase were
obtained with pneumococcal topo IV arrested on a 34 bp
E-site DNA by quinolone or quinazolinedione antibacter-
ials (18,19). Here, we describe X-ray crystal structures of
the ‘open’ clamp conformation of S. pneumoniae topo IV,
the ﬁrst to be reported for any type II topoisomerase. One
complex involving E-site DNA stabilized with levoﬂoxacin
was solved at 6.5 A˚; a second structure containing V-site
DNA and no drug was solved at 3.7 A˚ resolution, reveal-
ing two different DNA-binding sites. The latter complex
shows the structure and disposition of all three gates at
high resolution and has implications for topoisomerase
mechanism and drug design. Based on these observations,
we propose a plausible model for DNA capture and trans-
port by type II topoisomerases.
MATERIALS AND METHODS
Proteins and DNA
Plasmid cloning, protein expression and puriﬁcation of
S. pneumoniae full-length ParE and ParC55 proteins
have been described earlier (27,29). To produce the full-
length ParE-ParC55 fusion protein, Vent DNA polymer-
ase was used to amplify the parE gene using S. pneumoniae
7785 DNA as template. The forward primer (N7043) was
Figure 1. DNA strand passage by type II topoisomerases. A generic
scheme is shown whereby a transported DNA segment (maroon) is
passed through a transiently broken gate-DNA (green) by coordinated
action of N- (or ATPase), DNA- and C-gates. The diagram shows the
putative open (1) and closed clamp states (2–4) and putative conform-
ational transitions driven by ATP binding/hydrolysis and ADP release
(see text). ATPase and TOPRIM domains are shown in red and yellow,
respectively. The DNA breakage-reunion and C-terminal b-pinwheel
domains are depicted in grey and silver, respectively.
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50-AGGAGGTTCCATATGTCAAAAAAGG-30 and the
reverse primer (ParE NdeI-C) 50-AAAACATATGAAAC
ACTGTCGCTTCTTCTAGCGT-30 each contained an
NdeI restriction site (underlined). The PCR conditions
were as follows: denaturation at 94C for 1min, annealing
at 53C for 1min and polymerization at 72C for 3min.
Reactions were performed over 30 cycles. The parE
product was digested with NdeI and inserted into an
NdeI-digested pET29a plasmid upstream of parC
sequence encoding ParC55 that had been cloned as an
NdeI-XhoI fragment. The resulting parE-parC55 plasmid
was transformed into E. coli BL21(D3) pLysS, and the
ParE-ParC55 fusion protein bearing a C-terminal His6 tag
was overexpressed and puriﬁed to >95% homogeneity by
Ni-chelate chromatography. The fusion protein was cata-
lytically active promoting gemiﬂoxacin-induced DNA
cleavage (see Supplementary Figure S5) and exhibited
the expected basal level of DNA relaxation activity
(Crevel, I., Pan,X.S. and Fisher,L.M., results not shown).
DNA oligomers were synthesised by solid-phase
phosphoramidite chemistry and doubly high performance
liquid chromatography puriﬁed by Metabion, Munich.
Crystallization and data collection
Low-resolution complex (space group H32)
The low-resolution complex crystals of ParC55/ParE full-
length (N-terminally tagged)/26mer E-site DNA/levo-
ﬂoxacin were grown by the sitting drop technique in
standard MRC 96-well plates. First, the proteins were
dialysed overnight against 20mM Tris–HCl (pH 7.5),
1mM b-mercaptoethanol, 0.05% sodium azide and
200mM sodium chloride, then their concentrations were
measured and the 1:1 molar ratio mixture was formed (see
Figure 2A for domain composition of the proteins used).
After that the protein mixture was concentrated to 4mg/
ml, and the dialysis was repeated overnight against buffer
of the same composition but with a salt concentration of
100mM sodium chloride in the second step. Then, 10mM
MgCl2, 2mM levoﬂoxacin and 1:1.2 molar ratio of 26-mer
E-site DNA (see Figure 1B for E-site sequence) were
added (ﬁnal concentration). The mixture was pre-
incubated overnight at room temperature. The crystalliza-
tion drops were formed by mixing 600 nl of the protein
mixture with 400 nl of reservoir solution [50mM sodium
cacodylate (pH 6.5–7.0), 2.5% TacsimateTM (pH 7.0)
(Hampton Research Corp.) (33), 100mM sodium
chloride, 7.5mM magnesium chloride, 3–4% isopropa-
nol]. Crystals formed after several weeks at room tempera-
ture. The best crystals were ﬂash-cooled to 100K into a
cryoprotectant buffer [50mM Na cacodylate (pH 6.5),
2.5% TacsimateTM (pH 7.0) (Hampton Research Corp.)
(33), 62.5mM KCl, 7.5mM MgCl2, 1mM b-mercapto-
ethanol, 30% (v/v) MPD]. Crystals were formed in space
group H32 with cell dimensions a=b=213.58 A˚,
c=211.83 A˚, a= b=90 and g=120, the best overall
resolution was 6.53 A˚ (Supplementary Figure S1). Data
collection was performed at the Diamond synchrotron
(Oxfordshire, UK) using the 3rd generation beamline
I03, equipped at that time (2010) with an ADSC
detector. The wavelength for the data collection was set
to 0.9763 A˚. Data were integrated and reduced using Xia2
(XDS) (34–36).
High-resolution complex (space group P42212,)
Full-length ParE-ParC55 fusion protein (see Figure 2A for
domain composition of the protein used) at 3mg/ml con-
centration was dialysed against 20mM Tris–HCl (pH 7.5),
1mM b-mercaptoethanol, 0.05% sodium azide and
200mM or 100mM sodium chloride (initial and ﬁnal
steps, respectively). The dialysed protein was mixed with
the 34 bp V-site DNA (see Figure 2B for V-site sequence)
at 1:2.2 protein: DNA molar ratio. After that, 10mM
magnesium chloride and 2mM levoﬂoxacin (ﬁnal concen-
tration) were added, and the crystallization mixture was
incubated overnight at room temperature. Crystallization
was performed by conventional sitting drop vapour diffu-
sion in 96-well MRC crystallization plates (drop ratio:
600 nl+400 nl protein+reservoir, respectively). Crystals
grew after 7 days from 50mM sodium citrate (pH 5.0),
4–7% isopropanol and were also hard to reproduce due to
strong sensitivity to the pH of the crystallization solu-
tion—our subsequent experiments showed that deviation
of±0.1–0.15 pH units was sufﬁcient to step-over the crys-
tallization conditions. The crystals were ﬂash frozen into a
solution of 50mM sodium citrate (pH 5.0), 60mM sodium
chloride, 30% MPD, 4% isopropanol, 1mM b-mercap-
toethanol. Crystals were formed in space group P42212
with cell dimensions a=b=160.384 A˚, c=280.806 A˚,
a= b= g=90, the best overall resolution was 3.7 A˚
(Supplementary Figure S2). High-resolution data
collection was performed at the Diamond synchrotron
(Oxfordshire, UK) using 3rd generation beamlines
I04-1 and I24 equipped with Pilatus detectors (2012).
The wavelength for data collection was set to 0.92000 A˚.
Data were integrated and reduced using Xia2 (XDS)
(34–36).
Structure determination
Structures were solved by molecular replacement in Phaser
(35,37) using as search models our ParC55/ParE30/18mer
DNA+levoﬂoxacin structure (PDB ID: 3RAE) as a
starting model and a ParE ATP domain homology
modelled in 3D-JigSaw (38) on the basis of the structure
of the ATPase domain of the E. coli gyrase (PDB ID:
1EI1) (39).
The 34 bp DNA model from the structure of the
Saccharomyces cerevisiae (PDB ID: 2RGR) (17) was
found to be useful for extending our 18mer DNA model
for the high-resolution structure. In the high-resolution
structure, the second DNA molecule was discovered
during the initial reﬁnement and has been positioned
into difference Fourier density maps. As a consequence
of the V-site not having a palindromic sequence, and the
fact that the second DNA lies on a crystallographic 2-fold
symmetry axis, it was modelled using two alternative
orientations with ﬁxed occupancies of 0.5 (Supplementary
Figure S3).
The low-resolution structure was initially reﬁned in
CNS-Solve (40) using the DEN reﬁnement protocol (41).
Subsequent reﬁnement was performed in Phenix (42).
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However, despite heavy restraints, the structure looked
over-ﬁtted with gaps between R and R-free exceeding
10%, which is not surprising at such low resolution and
without a good starting model for the ATPase domain of
ParE. Therefore, for the ﬁnal deposited structure in space
group H32, the reﬁned protein model from our high-reso-
lution structure in space group P42212 was used to retroﬁt
the data and reﬁned with rigid body and TLS methods in
Phenix (42) (no individual xyz reﬁnement performed).
This approach allowed for the ﬁnal R/R-free of 0.2474/
0.2982 to be obtained, whereas no signiﬁcant changes to
the electron density maps were detected. The model was
inspected and manually corrected using the graphics
programWinCoot (43). The bound levoﬂoxacin drug mol-
ecules could easily be seen in the Fobs-Fcalc map and thus
were added to the ﬁnal model. According to ProCheck
(44), 774 residues (86.4%) are in most favoured regions
of Ramachandran plot, 108 residues (12.1%) are in add-
itional allowed regions, 9 residues (1.0%) are in gener-
ously allowed regions and 5 residues (0.6%) are in
disallowed regions.
As for the high-resolution structure in space group
P42212, reﬁnement was performed in Refmac (35,45,46)
during the initial stages using jelly body reﬁnement, grad-
ually increasing the resolution starting from 4.5 A˚ in steps
of 0.5 A˚. Subsequent reﬁnement was executed in Phenix
(42) using the secondary structure restraints derived from
the high-resolution structure of ParC55/ParE30/
18mer+levoﬂoxacin (PDB ID: 3RAE). Multiple rounds
of rigid body, positional and TLS reﬁnement were per-
formed, and the model each time was inspected and
manually corrected using the graphics program WinCoot
(43) after the reﬁnement cycle. According to ProCheck
(44), 1511 residues (82.7%) are in most favoured regions
of Ramachandran plot, 277 residues (15.2%) are in
additional allowed regions, 24 residues (1.3%) are in gen-
erously allowed regions and 16 residues (0.9%) are in dis-
allowed regions.
The ﬁnal data collection reﬁnement statistics are given
in Supplementary Table S1.
In both low- and high-resolution structures, it was not
possible to trace clearly the residues 400–413 of ParE,
which form a ﬂexible hinge joining ATPase and
TOPRIM domains owing to their high mobility.
However, the absence of extra electron density observed
above the bound G-segment DNA, the signiﬁcantly longer
distance from residue 399 to residue 414 of ParE on the
opposite side of the G-segment DNA-binding groove
(30.5 A˚) compared with the distance to the identical
residue 414 on the same side (15.5 A˚), and the requirement
that the G-gate be able to approach and bind in the
groove allowed us to conclude that the ATPase domains
are linked in cis to the TOPRIM domains to which they
are closest (i.e. lie on the same sides of the DNA binding
groove of ParC55). This is in contrast to the criss-cross
(trans) conformation observed in the ADPNP-closed
structure reported by Schmidt et al. (23).
Manuscript preparation
Initial model manipulations in preparation for movie gen-
eration were performed in WinCoot (43). Movies were
generated using custom-developed (by I.Laponogov)
script for CNS-Solve (40). The 3D representations of the
molecules were generated using VMD/Internal Tachyon
renderer (47) (Figures 3, 7–10 and Supplementary
Movies S1 and S2) or PyMOL (The PyMOL Molecular
Graphics System. Schro¨dinger, LLC.) (Figures 5, 6 and 8,
Supplementary Figures S1–S4, Supplementary Movie S1).
The core r.m.s.d. values were calculated using WinCoot
Figure 2. Streptococcus pneumoniae topo IV and its E and V cleavage sites on DNA. (A) Domain structures of 72 K ParE and 93K ParC subunits of
S. pneumoniae topo IV. Figure shows the recombinant non-fused (top), fused (middle) and native (bottom) ParE and ParC subunits. ATP and
TOPRIM denote N-terminal ATPase and C-terminal Mg2+ binding domains of ParE. CTD denotes the DNA binding C-terminal domain of ParC
that orients DNA for transport and which adopts a b-pinwheel structure. WHD indicates the winged helix domain. Numbers denote amino acid
residues in the 647 residue ParE and 823-residue ParC proteins. (B) DNA sequences of the 34mer V-site and 26mer E-site used in crystallization
studies. The 4-bp overhanging sequence which is generated upon cleavage between 1 and +1 nucleotides (arrows) is shown in red.
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(SSM) (43), crystallographic unit cell formation was
visualized in MapView (crystal lattice visualization
software developed by I.L. in our group) and rendered
using Pov-Ray (http://www.povray.org/). Movie assembly
was performed using SSMM (Slide Show Movie Maker
published by Joern Thiemann as freeware) with subsequent
editing in Corel VideoStudio Pro X3. Figures were
assembled and prepared using CorelDraw X5.
Data deposition
Atomic coordinates and structure factors have been
deposited in the PDB with accession codes 4I3H (high-
resolution structure, space group P42212) and 4JUO
(low-resolution structure, space group H32).
RESULTS AND DISCUSSION
‘Open’ ATP gate structure of topo IV from S. pneumoniae
Our initial attempts to crystallize a three-gate open clamp
complex of S. pneumoniae topo IV used recombinant full-
length ParE protein and a ParC55 protein comprising the
breakage-reunion domain of ParC (Figure 2A). Crystal-
lization trials were set up with differently sized oligo-
nucleotide duplexes in the presence and absence of
quinolones. A levoﬂoxacin-DNA cleavage complex of
ParE and ParC55 proteins with a 26mer E-site DNA
(Figure 2B) yielded a crystal structure in the rhombohe-
dral space group H32 with a best resolution of 6.5 A˚
(Supplementary Figure S1, Supplementary Table S1).
Though at low resolution, the structure clearly showed
an open clamp conformation with undimerized ParE
ATPase domains and clear conformations and dispos-
itions of the ATPase (N)-gate, the drug-bound DNA-
gate and C-gates (Supplementary Figure S1, PDB entry
4JUO). To obtain a structure at higher resolution, we
explored a number of modiﬁcations to the crystallization
protocol. First, to prevent subunit dissociation and
generate a stabilized complex, we engineered a catalytic-
ally active fusion protein comprising the full-length ParE
and breakage-reunion ParC55 domain (Figure 2A and
Supplementary Figure S5). Second, we used an alternative
gate-DNA, namely, a 34mer DNA duplex comprising the
plasmid V-site (Figure 2B), which we have shown is also
strongly cleaved by pneumococcal topo IV (Arnoldi ref).
Third, we experimented with 1:1.2 and 1:2.2 protein–DNA
ratios. Co-crystallization of the fusion protein with a
2.2-fold excess of V-site DNA yielded a crystal structure
in space group P42212 (Supplementary Figure S2) with the
best resolution of 3.7 A˚. This new structure reveals a novel
(ParE-ParC55)2 dimer complex bound to two DNA mol-
ecules and adopting the open clamp conformation
(open ParE N-gate; closed G and C gates) (Figure 3,
Supplementary Movie S1). Essentially, the same open
Figure 3. High-resolution ‘open clamp’ structure of S. pneumoniae topoisomerase IV bound to 34mer V-site DNA. The surface (left) and cartoon
(right) representations of the dimeric complex of fused full-length ParE-ParC55 are shown in orthogonal views. ParC55 is in silver, ParE N-terminal
gate domain (including the ATPase subdomain) is in red, ParE TOPRIM domain is in light pink, G-segment DNA is in green, the second DNA
bound to a-helices near the C-gate is in blue.
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clamp conformation and domain dispositions were seen
for this drug-free complex as was observed for the levo-
ﬂoxacin-stabilized 6.5 A˚ complex obtained in a different
space group using a different gate-DNA sequence and dif-
ferent crystallization conditions (Supplementary Figures
S1–S4).
From the high-resolution structure, the complex resem-
bles a bull’s head with the open N-gate forming the horns
(Figure 3, Supplementary Figures S2 and S4, Supplemen-
tary Movie S1). The overall dimensions of the complex are
190 A˚ 90 A˚ 120 A˚ and the total molecular weight
exceeds 287 kDa (counting 1/2 of the second DNA
molecule in Figure 3). The DNA bound at the G-gate is
bent and uncleaved and adopts an A-form conformation
immediately at the scission sequence while retaining
B-form on the ﬂanks (Figure 4), as seen previously for
drug-free DNA complexes of ParC55 with ParE30 (19).
By contrast, the second DNA molecule links each of four
complexes together within the crystal lattice by binding to
the long helices of the C-gate via ParC R468, K464, N461
and H196 residues (Figure 5, Supplementary Figure S3)
and is entirely in the linear unbent B-form (Figure 5).
Evidently, two different conformational states of the
V-site gate-DNA co-exist within the crystal under the
same conditions. Thus, in answer to a longstanding
question, it appears that the DNA gate sequence is
linear but undergoes both enzyme-induced bending and
helical transition from linear B- to a bent B-A-B-form
on binding as a DNA gate. The results support the sug-
gestion that distortion and bending of the DNA is
required for DNA scission at the gate (19).
Probing the non-gate DNA-binding site
The presence of a second DNA-binding site on ParC has
not been reported previously, and its unveiling is most
likely a consequence of the higher ratio of DNA used in
the crystallization conditions. The function of the site is
unknown but through DNA connectivity, it could in prin-
ciple have a role in G-gate stabilization or T-segment
alignment. In particular, the site is of interest in relation
to the position and orientation of the C-terminal
b-pinwheel domain of topo IV, which is believed to facili-
tate the T-segment orientation and transition through the
reversibly cleaved G-segment. In the case of gyrase, DNA
adjacent to the G-segment DNA is bent around the
b-pinwheel aligning it as a T-segment, ensuring intramo-
lecular DNA transport and resulting in negative supercoil-
ing of the DNA (1–4,9). However, the disposition of the
bpinwheel domain has yet to be established precisely in
the context of a full-length type II topoisomerase-DNA
complex. Our preliminary modelling showed that the
location of the second bound DNA is favourable for the
DNA interaction with the modelled C-terminal domain
of topoisomerase II in both of its plausible locations
(Figure 6) according to the accepted paradigm (1–4) as
well as to the results of the low-resolution SAXS studies
of gyrases (21,22). Of the four ParC residues engaged in
non-gate DNA-binding lie on the enzyme surface, and
that K464 and K471 (but not N461 and R468) are
conserved among ParC and GyrA proteins of E. coli,
Staphylococcus aureus and S. pneumoniae, suggesting func-
tional signiﬁcance (data not shown). To test this aspect,
we made a number of full-length ParC proteins in which
one or more residues in the second DNA binding were
altered to alanine or negatively charged glutamate and
tested their catalytic activity. Mutant S. pneumoniae
Figure 4. G-segment DNA in the high-resolution structure. Orthogonal
views of the bound G-segment V-site DNA with the 2Fobs-Fcalc electron
density map at 1.5s overlapped and the corresponding active site tyro-
sines-118 and arginines-117 displayed. The DNA form is indicated ac-
cording to w3DNA (48).
Figure 5. ParC subunit interactions with the second DNA duplex.
Four topo IV dimers coordinate the B-form DNA duplex in the
crystal with the corresponding ParC residues involved are shown in
red, yellow, green and blue. Green and red spheres show the positions
of water molecules. The DNA form is indicated according to w3DNA
(48).
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ParC (K464A), ParC (R468A) and triple mutants ParC
(K464A,R468A,K471A) and ParC (K464A, R468E,
K471E), all exhibited wild-type activities in DNA
decatenation, DNA relaxation and DNA cleavage assays
when reconstituted with ParE (Pan, X-S., Sarigul, M. and
Fisher, L.M., results not shown). Thus, although the
second DNA coordinates four topo IV dimers in the
crystal, mutagenesis of this interface did not appear to
alter catalytic activity, with the proviso that we did not
examine relaxation of positively supercoiled DNA,
another topological form discriminated by topo IV.
Moreover, we cannot presently rule out a biological role
involving higher-order structure through concerted coord-
ination of different topo IV molecules.
ATPase domains
The complex was crystallized in the absence of ATP and
reveals novel aspects of the open N-gate conformation
(Figure 3). The two N-terminal ParE ATPase domains
(residues 1–399 shown in red in Figure 3) (that dimerize
on ATP binding to close the N-gate) are located far apart
fully exposing the G-segment (in green) to the solvent
from above (Figure 3, Supplementary Movie S1). The
ATPase subdomains (residues 1–220) are located distal
to the main body of the complex, with the rest of the
gate (residues 221–399) sitting on top of the core
complex with long a-helices (ParE residues 373–399) oc-
cupying the groove between the ParC55 ‘Tower’ (shown in
silver) and the ParE TOPRIM domain (shown in light
pink) with their polar side chains mainly exposed to
solvent above the complex suggesting a possible role in
T-segment capture. The overall domain orientation resem-
bles that predicted for E. coli gyrase in solution using low-
resolution SAXS data (21,22) and electron microscopy
(20). The N-terminal ParE domains were easily traceable
with the exception of a few disordered loops (Figure 7A
and C for the analogous Xanthomonas oryzae ATPase
domain), which are ordered in previously solved
ADPNP-induced dimers of ATPase domains examined
in isolation (39,49) (Figure 7B and D, Supplementary
Movie S2). These regions include the ﬁrst 19 amino
acids of ParE, which participate in interdomain linkage
on ATP binding and help form the nucleotide binding
site. In our structure, the ATP binding site is empty and
covered by the neighbouring a-helix from the same ParE
monomer, plausibly protecting it from ATP binding
before T-segment capture (Figure 7A), a feature not pre-
viously observed in other crystal structures of the ATPase
domains of ParE and GyrB dimers (Figure 7B–D) (39,49).
Interestingly, the N-terminal gate is connected to the
TOPRIM domain (residues 400–647) of ParE via a
single ﬂexible linkage comprising residues 400–413
bridging a distance of 15.5 A˚ (Figure 3). The protein link
allows for pivoting and dimerization of ParE domains ne-
cessary for N-gate closure. The link is mobile and poorly
ordered, so its exact fold is not evident from the crystal-
lographic data. However, it is clear that in the open clamp
conformation, linkage of the N-gate domains to the
TOPRIM domains of ParE occurs on the ‘same’ sides of
the heterodimer (see Figure 3 and ‘Materials and
Methods’ section for explanation) and does not criss-
cross between the two sides of the complex, which
would otherwise impede DNA transport (Figure 1).
A mechanism for DNA capture and transport
The new features revealed in the open enzyme conform-
ation together with available partial structures suggest a
plausible model for DNA capture and strand passage by
Figure 6. Putative binding positions of the modeled C-terminal b-
pinwheel domain of ParC relative to the solved biological dimer and
the second DNA-binding site. ParC55 is in cyan, ParE N-terminal gate
domain (including the ATPase subdomain) is in red, ParE TOPRIM
domain is in light pink, G-segment DNA is in green, the second DNA
bound to a-helices near the C-gate is in blue. The model of the C-
terminal b-pinwheel domain of ParC is in silver with additional semi-
transparent surface representation.
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the complex (shown in Figure 8 and animated in
Supplementary Movie S2). Initially, the ‘open and
welcoming’ conformation of the ATPase domains
(Figure 3) allows for the unhindered approach of the
G-segment DNA, which on binding undergoes distortion
from linear B-form to the bent and extended A-form
DNA gate (Figures 3, 4 and 8, stages 1–3). Next, the
T-segment approaches (perhaps pre-coordinated by the
‘Towers’ and the long a-helices of the ATPase domains)
and undergoes transient capture by upward 90 rotation
of t he ATPase domains around the pivoting points, which
shifts them closer by a few A˚ngstroms [in accordance with
conformation of the ADPNP-stabilized GyrB NTD dimer
from E. coli gyrase, PDB code: 1EI1, which was used to
model the closed ATPase domains with ATP bound (39)]
(stage 4). On capture, the T-segment will be located in the
middle cavity of the ATPase domain dimer between the
ATPase site at the top and the crossed long a-helices
(residues 373–399) at the bottom (Figure 8, stage 4–6).
This cavity is large enough to accommodate a captured
DNA duplex and has the a-helices comprising residues
285–305 and 317–321 at the exact distance and position
to intercalate into the major groove of the DNA, thus
stabilizing binding (stage 5). Sensing the presence of
both the T-segment and G-segment (relayed by the posi-
tively charged K-loop (23), a conformational transducing
element in the ATPase domain critical for catalysis), the
ATPase domains recruit ATP and undergo rearrangement
of several loops in the active site, particularly the known
cross interpolation of the ﬁrst 20 residues of ParE,
forming the ATP-binding site and locking the dimerized
ATPase domains together (stage 6) as shown in Figure 8
and Supplementary Movie S2 (However, at this point, it is
not clear if the ATP needs to be pre-bound to the incom-
plete binding site to ‘prime’ the ATP domains and make
them ready to capture the T-segment or the capture
happens ﬁrst and then the ATP binds and locks the
assembly). These events tighten the whole arrangement
prompting DNA cleavage and opening of the G-gate
formed by the ParC55 and ParE TOPRIM domains
(stage 7) (modelled on the opened conformation of full-
length ParC from E. coli, PDB code: 1ZVU) (6). DNA
cleavage is aided by the strain and torsional stress
present in the helically distorted and bent gate-DNA
facilitating attack by active-site tyrosines (Y118 of
ParC). When the DNA-gate opens sufﬁciently to pass
the T-segment (36 A˚ in our model), the simultaneous
spring action of the long a-helices of the ATPase
Figure 7. The ATPase domains. Shown are cartoon representations of the ATPase domains of ParE or GyrB in S. pneumoniae (top left), E. coli
[right top and bottom for GyrB (39) and ParE (49), respectively) and X. oryzae ParE (Heo, Y.-S. Crystal structure of ParE subunit. PDB code:
3LNU). Where applicable, the domains are in their dimerized form stabilized by ADPNP, a non-hydrolysable ATP analogue (displayed in Licorice
mode). An ‘ATPase-active site covering’ a-helix present in S. pneumoniae ParE and its analogue in other structures is shown in red. ADPNP in B and
D is shown in gold.
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Figure 8. Proposed model for the T-segment DNA capture and transport based on the high-resolution structure of the open N-gate topoisomerase
complex with the V34 G-segment DNA. The individual distinct stages are numbered 1 to 14. The protein is shown in Cartoon representation, the
DNA is shown in surface representation. The ParE ATPase and TOPRIM domains are shown in red/light red for one side and yellow/light yellow
for the other one, with dotted lines indicating the ﬂexible poorly ordered protein pivot corresponding to S. pneumoniae ParE residues 399–413. The
G-segment is in green, the T-segment is in cyan and ParC55 is in silver. ATP/ADP+leaving phosphates are shown in van der Waals representation
and coloured according to the atom type. Residues 303–316 of ParE comprising the K-loop (23) are shown in blue where applicable and the
corresponding arginine/lysine Ca-s are shown in purple using van der Waals representation (stages 6 and 12, indicated by asterisks and arrows).
Small arrows indicate general movements of the domains, whereas the larger arrows indicate progress through the topo II cycle. The open clamp
state (stage 2 and 14) and its conversion to the closed clamp form (stage 5) are new ﬁndings from our study. There is uncertainty about exactly how
the two ATP molecules are used and whether all type II topoisomerase systems follow the same hydrolytic mechanism. For simplicity and to focus
on the pathway of DNA transport, we show both ATP molecules hydrolyzed at stage 12, though one molecule could be hydrolysed earlier (at stage 7
and 8) as postulated for yeast topo II (2,3).
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domains rotate the T-segment by 45, presenting it
almost perpendicular to the G-segment (stage 7). This
domain rearrangement also moves the long ParE
a-helices previously blocking the T-segment out of the
way allowing DNA transport through the DNA gate.
Once the T-segment reaches the lower cavity in the
heterotetramer next to the C-gate (stage 8), the G-gate
closes and is resealed (stage 9) coordinated with
T-segment release via the opening and closure of the
C-gate (stages 10 and 11). Closure of the G-gate is
achieved most simply by reverse 45 rotation of the
ATPase domain dimer bringing it back to the original
Figure 9. ‘Open’ and ‘closed’ ATP gate conformations known from crystallographic structures. (A) ‘open’ ATP gate structure of pneumococcal topo
IV (this work); (B) ‘closed’ ATP gate structure of yeast topo II (23). The structures are displayed in ‘surface’ mode in orthogonal views.
Corresponding ParE domains are shown in red/yellow. G-segment is in green. ParC55 domains in (A) are in cyan. ParC55-equivalent domains in
(B) are in white. (C) Diagram superimposing the hinge regions of open and closed clamps of type II topoisomerases. For the open clamp topo IV
structure, linkage of ATPase and TOPRIM domains (shown in yellow) through their respective ParE S399 and G414 residues (black dotted line)
occurs on the same side of the complex, whereas for the closed clamp of yeast topo II, the ﬂexible hinge linking E408 and to S421 (red dotted line)
passes over the bound DNA (shown in green) to connect ATPase and TOPRIM domains on opposite sides of the gate.
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position with the K-loop contacting the G-segment,
inducing ATP hydrolysis, releasing ADP and resetting
the ATPase domains back to the open conformation
(stages 12–14) (Figure 8, Supplementary Movie S2).
Interconversion between ‘open’ and ‘closed’ conformations
of the ATPase domains
Transition between open and closed clamp states is a
central feature of the type II topoisomerase reaction
cycle (Figure 1, Supplementary Movie S2). Intriguingly,
comparison of our open clamp topoisomerase IV structure
with the closed structure of yeast topo II determined at
4.4 A˚ (23) reveals a markedly different disposition of
ATPase domains that has potentially important implica-
tions (see Figure 9). In the yeast topo II structure, the
ATPase domains are locked with ADPNP into a dimerized
state in the absence of a T-segment, and the DNA gate is
trapped in the cleaved state using a suicide DNA substrate
(Figure 9B, PDB entry 4GFH) (23). The structure is sug-
gested to be a snapshot of topo II after the T-segment
transport and before the ADP release. Interestingly, in
contrast to the open enzyme clamp (Figures 3 and 9A),
the ATPase domains of the closed clamp structure are in
a criss-cross orientation (bordering a collapsed cavity),
which would require rotations of the ATPase domains of
>225 in closing the G-gate and then in resetting to the
open clamp form (see Figures 8 and 9). If the closed clamp
structure represents a reaction intermediate, then transi-
tion to a crisscrossed arrangement could act as an irrevers-
ible switch ensuring directional DNA transport (23). Such
a large conformational change differs from the modest 45

reverse rotation shown in Figure 8, which is attractive in
that it allows the enzyme to achieve enzyme turnover with
minimal movement and at the same time being supported
by the results of biochemical studies of the role of the
K-loop master sensor (23).
After our manuscript submission, a cryo-electron mi-
croscopy structure was described for an ADPNP-gyrase-
DNA complex bound to ciproﬂoxacin and stabilized by
glutaraldehyde cross-linking (50). Based on this closed
clamp structure determined at 23 A˚ resolution, it was sug-
gested that ATPase-TOPRIM domain cross-over occurs
to trap the translocated DNA before DNA strand
passage (Figure 1, transition 1 to 2). This arrangement
differs from our open clamp topo IV structure at 3.7 A˚,
which clearly lacks crossovers and is of course a different
conformational state in the reaction cycle. Obviously, the
poor resolution of cryoEM structures makes it more dif-
ﬁcult to trace domain linkage with certainty. However,
crossovers could be a feature of type II topoisomerase
action that occur at different stages in the reaction trajec-
tory for topo IV, gyrase and topo II. Clearly, high-reso-
lution X-ray structures will be needed to deﬁne exactly
what conformational transitions occur after clamp
closure.
The open clamp structure and rational design of cleavage-
enhancing drugs
Several structures of type II topoisomerase cleavage
complexes have been reported recently by us (18,19) and
others (16,51,52) comprising the ParE30/ParC55 domains
of the topo IV [or equivalent for gyrase (16) and human
topo IIb (52)] with the G-segment DNA bound and
stabilized by antibacterials (16,18,19,16,51) or anticancer
drugs (52). These structures are the key ‘stepping stones’
for future rational drug design, which will be needed to
produce potent antibacterial (and anticancer) therapies
that overcome drug resistance. The partial structures
reveal very nicely the mode of binding of antibacterial
diones (Figure 10A) or quinolones or of anticancer
drugs at the DNA gate. However, the absence of
ATPase domains leads to some uncertainties in modelling
the scope and accessibility of drug binding pockets, as
suggested by the closed clamp structure (Figure 9) (23)
in which the ATPase domains adopt the criss-cross con-
formation and partially shield the DNA binding groove
from the solvent above. Reassuringly, the open clamp
structure of full-length topo IV reveals that the ATPase
Figure 10. Structural implications for rational drug design. (A) Previously published cleavage complex of topo IV from S. pneumoniae stabilized
by PD 0305970 (19) with the bound drug molecules shown in blue. (B) Corresponding view of the high-resolution structure of topo IV from
S. pneumoniae comprising the full-length ParE domains. ParC55 is in silver, G-segment DNA is in green, ParE is in red/yellow. The area available for
rational drug design exploration and exploitation is indicated by the blue/white ellipse. The locations of the ﬂexible pivot links between the ATPase
and TOPRIM domains of ParE are in white/red circles.
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domains are folded back, and the DNA gate is fully ac-
cessible to drugs from solvent above (Figure 10B and in
the lower resolution levoﬂoxacin complex, Supplementary
Section). As long as the areas immediately close to the
ends of the long a-helices of the ATPase domains are
avoided, the entire DNA-binding groove within the
bound G-segment can be exploited to design new gener-
ations of cleavage enhancing drugs (Figure 10). Thus,
modelling efforts based on structures of the more readily
available cleavage complexes lacking ATPase domains
appear to be a reasonable surrogate for the holoenzyme.
SUMMARY
We have solved the ﬁrst high-resolution open-clamp struc-
ture of a type II topoisomerase-DNA complex complete
with N-, DNA- and C-gates containing both bent gate-
DNA and a second linear DNA duplex bound at a previ-
ously unreported site on ParC. This second DNA duplex
reveals the ﬁrst structure of a gate-DNA before associ-
ation and bending at the gate. In our open clamp struc-
ture, the ATPase domains are folded back and linked to
TOPRIM domains on the same side of the enzyme
complex, two features that ensure full access for DNA
and cleavage enhancing drugs. Based on these structural
insights, we propose a mechanism for DNA capture and
transport by type II topoisomerases. The work signiﬁ-
cantly advances understanding of the initial steps by
which a macromolecular machine can recognize, capture
and transport DNA, a key process in managing the topo-
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